Genes2Me is a leading IVD solutions manufacturer from India, established in 2016 with a focus on revolutionizing molecular diagnostics. The company offers a wide range of innovative solutions including NGS clinical panels, molecular POC testing kits, RT-PCR kits, rapid antigen/antibody testing kits, and molecular biology reagents. Moreover, Genes2Me is renowned for its genetic testing services covering infectious and non-infectious diseases, oncology, rare diseases, and prenatal/postnatal genetic conditions.
The company's NGS clinical assays cater to targeted testing for various conditions such as Oncology, Liquid Biopsy, cardiovascular conditions, neurological disorders, and HLA typing. Noteworthy innovations from Genes2Me include their flagship products Rapi-Q/ Rapi-Q HT and Rapid POC RT-PCR device, which are set to revolutionize molecular Point of Care testing worldwide.
With an impressive lineup of offerings including CliSeq NGS clinical panels, PanCan, Med4Me, Exome CliSeq, CliSeq LiqBio, Rapi-Q / Rapi-Q HT, Rapi-X 16, Rapi-X 96, RapiCycler 96, RT-Direct, CoviEasy, and LeoNext, Genes2Me showcases its commitment to advancing the field of molecular diagnostics.
As of now, there is no publicly available information regarding the company's last investment or the involved investors. With its dedication to bringing revolutionary IVD solutions to the market, Genes2Me presents an intriguing opportunity for potential investors seeking to tap into the biotechnology, healthcare, and manufacturing sectors in India.
